Browsing by Author "Senel, K"

Now showing 1 - 5 of 5
  • No Thumbnail Available
    Item
    Femoral cartilage thickness measurements in healthy individuals: Learning, practicing and publishing with TURK-MUSCULUS
    Özçakar, L; Tunç, H; Öken, Ö; Ünlü, Z; Durmus, B; Baysal, Ö; Altay, Z; Tok, F; Akkaya, N; Dogu, B; Çapkin, E; Bardak, A; Çarli, AB; Bugdayci, D; Toktas, H; Diraçoglu, D; Gündüz, B; Erhan, B; Kocabas, H; Erdenn, G; Günendi, Z; Kesikburun, S; Omaç, ÖK; Taskaynatan, M; Senel, K; Ugur, M; Yalçinkaya, EY; Önes, K; Atan, Ç; Akgun, K; Bilgici, A; Kuru, Ö; Özgöçmen, S
    BACKGROUND AND OBJECTIVES: Measurement of the femoral cartilage thickness by using in-vivo musculoskeletal ultrasonography (MSUS) has been previously shown to be a valid and reliable method in previous studies; however, to our best notice, normative data has not been provided before in the healthy population. The aim of our study was to provide normative data regarding femoral cartilage thicknesses of healthy individuals with collaborative use of MSUS. METHODS: This is across-sectional study run at Physical and Rehabilitation Medicine Departments of 18 Secondary and Tertiary Centers in Turkey. 1544 healthy volunteers (aged between 25-40 years) were recruited within the collaboration of TURK-MUSCULUS (Turkish Musculoskeletal Ultrasonography Study Group). Subjects who had a body mass index value of less than 30 and who did not have signs and symptoms of any degenerative/inflammatory arthritis or other rheumatic diseases, history of knee trauma and previous knee surgery were enrolled. Ultrasonographic measurements were performed axially from the suprapatellar window by using linear probes while subjects' knees were in maximum flexion. Three (mid-point) measurements were taken from both knees (lateral condyle, intercondylar area, medial condyle). RESULTS: A total of 2876 knees (of 817 M, 621 F subjects) were taken into analysis after exclusion of inappropriate images. Mean cartilage thicknesses were significantly lower in females than males (all p < 0.001). Thickness values negatively correlated with age; negatively (females) and positively (males) correlated with smoking. Men who regularly exercised had thicker cartilage than who did not exercise (all p < 0.05). Increased age (in both sexes) and absence of exercise (males) were found to be risk factors for decreased cartilage thicknesses. CONCLUSION: Further data pertaining to other countries would be interesting to uncover whether ethnic differences also affect cartilage thickness. Collaborative use of MSUS seems to be promising in this regard.
  • No Thumbnail Available
    Item
    Open, Prospective, Multi-Center, Two-Part Study of Patient Preference with Monthly Ibandronate Therapy in Women with Postmenopausal Osteoporosis Switched From Daily or Weekly Alendronate or Risendronate-BONCURE: Results of Turkish Sub-Study
    Eskiyurt, N; Irdesel, J; Sepici, V; Ugurlu, H; Kirazli, Y; Ardiç, F; Bütün, B; Akyüz, G; Cerrahoglu, L; Sendur, ÖF; Yalçin, P; Öncel, S; Saridogan, M; Sarpel, T; Tosun, M; Kutsal, YG; Senel, K; Gürsoy, S; Cantürk, F; Demir, H; Özdener, F; Öncel, H
    Aim: BONCURE (Bonviva for Current Bisphosphonate Users Regional European Trial), aimed to evaluate patient preference with monthly ibandronate in women with postmenopausal osteoporosis who previously received daily or weekly alendronate or risendronate. Materials and Methods: This prospective, open-label study consisted of two sequential stages, Part A (screening) and Part B (treatment). Patients enrolled into Part A completed the Candidate Identification Questionnaire (CIQ). In Part B, after completing the Osteoporosis Patient Satisfaction Questionnaire (OPSATQ), patients received monthly oral ibandronate 150 mg for 6 months. Following treatment, patients completed the OPSAT-Q and Preference Questionnaire. Results: A total of 223 patients (mean age, 63.7 +/- 9.51 years) were enrolled in Part A from Turkey. Among them, 103 (46.2%) answered YES to at least one CIQ question. The mean composite OPSAT-Q domain scores increased for convenience (mean change, 15.3 +/- 17.7 points), quality of life (10.4 +/- 20.4 points), overall satisfaction (11.9 +/- 22.7 points), and side effects (3.3 +/- 18.8 points). At month 6, 177 subjects (92.7%) preferred once-monthly dosing schedule and 99.0% were compliant (>= 80%) with study treatment. Thirty (15.6%) subjects experienced mild to moderate adverse events, mostly gastrointestinal. Conclusion: Postmenopausal women with osteoporosis prefer and are more satisfied and compliant with monthly dosing of ibandronate than daily or weekly bisphosphonate treatment. (Turkish Journal of Osteoporosis 2012; 18: 1-7)
  • No Thumbnail Available
    Item
    A CANDIDATE INDENTIFICATION QUESTIONNAIRE FOR PATIENTS WITH POSTMENOPAUSAL OSTEOPOROSIS SWITCHED FROM TREATMENT WITH A DIALY OR WEEKLY BISHPOSPHONATE TO ONCE-MONTHLY IBANDRONATE-BONCURE: RESULTS OF TURKISH SUB-STUDY
    Eskiyurt, N; Sendur, OF; Yalcin, P; Oncel, S; Saridogan, M; Sarpel, T; Tosun, M; Kutsal, YG; Senel, K; Gursoy, S; Canturk, F; Irdesel, J; Demir, H; Ozdener, F; Oncel, H; Serpici, V; Ugurlu, H; Kirazli, Y; Ardic, F; Butun, B; Akyuz, G; Cerrahoglu, L
  • No Thumbnail Available
    Item
    A candidate-identification questionnaire for patients with postmenopausal osteoporosis switched from treatment with a daily or weekly bisphosphonate to once-monthly ibandronate
    Kutsal, YG; Eskiyurt, N; Irdesel, J; Sepici, V; Ugurlu, H; Kirazli, Y; Ardic, F; Korsic, M; Vlak, T; Grlickov, M; Temelkova, SM; Lazarov, M; Pilipovic, N; Popovic, V; Dimic, A; Kovacev, B; Ruci, D; Tafaj, A; Kucukalic-Selimovic, E; Avdic, D; Seleskovic, H; Pejicic, S; Butun, B; Akyuz, G; Cerrahoglu, L; Sendur, OF; Yalcin, P; Oncel, S; Saridogan, M; Sarpel, T; Tosun, M; Senel, K; Gursoy, S; Cantürk, F; Demir, H; Miskic, B; Krpan, D; Skreb, F; Grazio, S; Crncevic-Orlic, Z; Ozdener, F; Oncel, H
  • No Thumbnail Available
    Item
    Prevalence of Rheumatoid Arthritis and Spondyloarthritis in Turkey: A Nationwide Study
    Tuncer, T; Gilgil, E; Kaçar, C; Kurtais, Y; Kutlay, S; Bütün, B; Yalçin, P; Akarirmak, Ü; Altan, L; Ardiç, F; Ardiçoglu, Ö; Altay, Z; Cantürk, F; Cerrahoglu, L; Çevik, R; Demir, H; Durmaz, B; Dursun, N; Duruöz, T; Erdogan, C; Evcik, D; Gürsoy, S; Hizmetli, S; Kaptanoglu, E; Kayhan, Ö; Kirnap, M; Kokino, S; Kozanoglu, E; Kuran, B; Nas, K; Öncel, S; Sindel, D; Orkun, S; Sarpel, T; Savas, S; Sendur, OF; Senel, K; Ugurlu, H; Uzunca, K; Tekeoglu, I; Guillemin, F
    Objectives: This study aims to estimate the prevalence of rheumatoid arthritis (RA) and spondyloarthritis (SpA) in Turkey using the same telephone questionnaire developed for screening RA and SpA in France and used in Serbia and Lithuania. Material and methods: The study was performed in two steps. In step I, the French questionnaire was translated into Turkish and validated through a group of 200 patients (80 males, 120 females; mean age 44.0 +/- 13.1 years; range, 19 to 75 years) followed up at the rheumatology departments of University Hospitals in Antalya and Ankara. In step II, the validated Turkish questionnaire was administered face-to-face to randomly selected 4,012 subjects (1,670 males, 2,342 females; mean age 41.5 +/- 16.8 years; range, 16 to 97 years) by trained general practitioners across the country, in 25 provinces for case detection. The subjects who were suspected of having RA or SpA in accordance with the questionnaire were invited to the nearest university hospital for rheumatologic examination in order to confirm the diagnosis. Results: In step II, a total of 25 subjects (2 males, 23 females) were diagnosed as RA. The standardized RA prevalence for the general population of Turkey was calculated as 0.56% (95% confidence interval [CI]; 0.33-0.79), 0.10% (95% CI; -0.05-0.25) for males and 0.89% (95% CI; 0.51-1.27) for females. A total of 18 subjects (3 males, 15 females) were diagnosed as SpA. The standardized SpA prevalence for the general population of Turkey was 0.46% (95% CI; 0.25-0.67), 0.17% (95% CI; -0.03-0.37) for males and 0.65% (95% CI; 0.32-0.98) for females. The prevalence of RA was highest in the Northern region (2.00%) and the prevalence of SpA was highest in the Central region (1.49%). Conclusion: The prevalences of RA and SpA in Turkey are close to each other and there are significant inter-regional variations in prevalences of both RA and SpA.